Cosibelimab: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Cosibelimab. Educational only — not medical advice.

Labeled uses

UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

Source: FDA labeling via NIH DailyMed (set 06bdadd5…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.